According to researchers at Weill Cornell Medical College in the Sept. 15 issue of the journal Cancer Research, taxne-based chemotherapy drugs are not well understood as they may be more powerful than many have believed. Generally, it is believed that taxane chemotherapy (paclitaxel, docetaxel and cabazitaxel) just stop a cancer cell from dividing -- but [...]
In an updated study published in the New England Journal of Medicine men who had a radical prostatectomy did not enjoy the experience of a reduced all-cause mortality or prostate cancer mortality compared with those men who had only observation through several years of follow-up. The subject men had localized prostate cancer often detected by [...]
In a study conducted by Choueiri et al. published in Cancer it was suggested that men who have prostate cancer that was treated by a radical prostatectomy (RP) who then had a long time to a biochemical recurrence (BCR) or a long PSA doubling time after a BCR have no higher overall risk of death [...]
Johns Hopkins Kimmel Cancer Center along with Danish researchers have announced the development of a novel, investigational anticancer drug (G202) that has been described as a molecular grenade that targets cancer cells. The drug is able to travel undetected by normal cells through the bloodstream until it is activated by a specific cancer proteins, then [...]
Here's a great opportunity to participate in an advanced prostate cancer marketing survey, earn $40 dollars for yourself and help move our understanding of our disease just a little bit further forward. What is the purpose? Understanding patients' knowledge and perceptions of treatments for prostate cancer, so researchers can understand how prostate cancer affects patients [...]